|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1981-2-26
|
|
pubmed:abstractText |
1 Seven normal volunteers received oral doses of 100 mg dapsone (DDS), 25 mg pyrimethamine (PYR) singly or in combination in random order. 2 Plasma and salivary DDS and plasma monoacetyldapone (MADDS) and PYR were estimated simultaneously by a hitherto unpublished quantitative absorption thin layer chromatographic method. This assay was shown to be satisfactory for pharmacokinetic studies. 3 The half-life of DDS was unaltered by PYR but the apparent volume of distribution was significantly increased from a mean of 1.53 1 kg-1 to 1.93 1 kg-1 and the peak DDS plasma levels measured fell by 17%. 4 The pharmacokinetic parameters of PYR were unchanged by DDS. 5 The half-life of MADDS was unchanged by PYR and was not affected by the acetylator status of the subject. 6 Salivary DDS excretion reflects the free plasma DDS concentration. Administration of PYR with DDS significantly alters the mean saliva/plasma DDS ratio from 0.265 to 0.358 suggesting an increase in free DDS with PYR therapy. 7 In vitro studies of plasma protein DDS binding indicate that DDS binds to a single class of binding sites on human plasma protein and PYR competitively displaces DDS from these sites. 8 The usefulness of salivary drug measurements in detecting increases of free drug in plasma in man is demonstrated.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437265-1182795,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437265-13617598,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437265-13993147,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437265-168216,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437265-26555,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437265-4559067,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437265-4583459,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437265-4584155,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437265-4741375,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437265-5133908,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437265-541369,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437265-5554939,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437265-5652701,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437265-668796,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437265-7371704,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437265-780085
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0306-5251
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
519-24
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1980
|
|
pubmed:articleTitle |
Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
